Repligen (NASDAQ:RGEN) Shares Gap Down – Time to Sell?

Repligen Co. (NASDAQ:RGEN) gapped down before the market opened on Tuesday . The stock had previously closed at $149.21, but opened at $145.00. Repligen shares last traded at $148.09, with a volume of 203,613 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RGEN. Stephens reissued an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Benchmark reissued a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and cut their price target for the company from $180.00 to $155.00 in a report on Wednesday, June 26th. Finally, JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Down 3.2 %

The company has a market capitalization of $8.09 billion, a P/E ratio of -3,729.32, a price-to-earnings-growth ratio of 4.24 and a beta of 0.95. The company has a 50-day moving average of $145.11 and a two-hundred day moving average of $147.91. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm had revenue of $154.07 million for the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the firm earned $0.53 EPS. The company’s revenue was down 3.2% compared to the same quarter last year. On average, research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now owns 19,261 shares in the company, valued at approximately $3,190,969.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. CWM LLC grew its position in Repligen by 19.9% during the first quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the period. Artemis Investment Management LLP lifted its holdings in shares of Repligen by 33.8% in the first quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after buying an additional 42,380 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Repligen by 21.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock valued at $61,767,000 after acquiring an additional 59,903 shares in the last quarter. State of Michigan Retirement System increased its holdings in Repligen by 2.4% in the 1st quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company’s stock valued at $2,346,000 after acquiring an additional 300 shares during the last quarter. Finally, Norden Group LLC lifted its stake in Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after purchasing an additional 36,663 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.